CVO-500: Monoclonal Anti-human Ron Antibody

Ordering Information
Catalog Number: CVO-500
Clone number: C9B
Size: 200 µl

Source: mouse monoclonal

Isotype:

Specificity: Human Ron protein

Immunogen: Ron extracellular domain



Flow Cytometry analysis using SW620 cells without primary C9B antibody.



Flow Cytometry analysis using SW620 cells with C9B antibody. U937 cells, which do not express Ron, show no significant flourescence with or without C9B antibody.

Background: The RON receptor tyrosine kinase is a member of the MET proto-oncogene family. Ron is expressed in epithelial cells and tissue macrophages and contributes to the malignant progression of various cancers. RON has a MW of 180 kD composed of a 40 kD α-chain and a 145 kD β-chain.

Production: Mice were immunized with human RON protein obtained from mammalian cell culture. The IgG fraction from the hybridoma supernatants was purified by Protein G affinity chromatography. Antibody is provided as a 0.7 mg/ml solution in PBS.

Storage: Recommended short-term storage at 4º C. Avoid repeated freeze-thaw cycles.

Applications: Flow Cytometry. Recommended dilution of 1:25.

References:

Wang, M.-H., Ronsin, C., Gesnel, M.-C., Coupey, L., Skeel, A., Leonard, E.J. and Breathnach, R. Identification of the RON gene product as the receptor for the human macrophage stimulating protein. **Science**. 1994, 266:117-119.

Zhou, Y.-Q., Wang, D., Jiang, Y.-H., and Chen, Y.-Q., and Wang, M.H. Altered expression of the RON receptor tyrosine kinase in primary colorectal carcinomas: generation of different splicing variants and their biological significance. **Oncogene** 2003, 22:186-197.

Xu, X.-M, Wang, D., Shen, Q., Chen, Y.-Q., Wang, M.-H. RNA-mediated gene silencing of the RON receptor tyrosine kinase alters oncogenic phenotypes of human colorectal carcinoma cells. **Oncogene**, 2004, 28:8464-8474.

Wang, M.H., Lee, W, Luo, Y.L., and Yao, H.P. Altered expression of the receptor tyrosine kinase in various epithelial cancers and its contribution to tumorigenic phenotypes in thyroid cancer cells. **J. Pathol.** 2007, 213:402-411.